Predicting response to immune checkpoint blockade therapy among mismatch repair-deficient patients using mutational signatures
D. Gulhan(Harvard University), Peter J. Park(Harvard University), James M. Cleary(Brigham and Women's Hospital), Francesc Muyas(European Bioinformatics Institute), Hu Jin(Harvard University), Michael B. Foote(Memorial Sloan Kettering Cancer Center), Viktor Ljungström(Uppsala University), Vinay Viswanadham(Harvard University), Jake June-Koo Lee(Memorial Sloan Kettering Cancer Center), Steven B. Maron(Memorial Sloan Kettering Cancer Center), Youngsook L. Jung(Brigham and Women's Hospital), Alon Galor(Harvard University), David Barras(Ludwig Cancer Research), Bill H. Diplas(Duke University), Isidro Cortés‐Ciriano(European Bioinformatics Institute), Benoı̂t Rousseau(Memorial Sloan Kettering Cancer Center)
Cited by 4
Related Papers
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
|Nature|2017|2k
The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma
|Cancer Cell|2014|860
Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
|New England Journal of Medicine|2019|808
A molecular portrait of microsatellite instability across multiple cancers
|Nature Communications|2017|671
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
|Cancer Cell|2017|656